BOSTON, Nov. 14, 2025 /PRNewswire/ -- Volta Labs, a leader in automation for genomics, and New England Biolabs® (NEB®), a world-renowned...
Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA...
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Streamlined, high-throughput sequencing of Influenza A virus with integrated indexing for Oxford Nanopore Technologies® platforms IPSWICH, Mass., Nov. 13, 2025...
THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A...
NEW YORK, Nov. 12, 2025 /PRNewswire/ --Imagine going to the pharmacy and getting an adhesive bandage that applies gentle energy...
Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000 U.S. Women in 2026 SAN JOSE,...
BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more...
After 25+ years in VA infectious diseases and national leadership, Echevarria joins Bitscopic to help VAMCs strengthen antimicrobial stewardship programs (ASP)...
New data from Ascend's R&D team demonstrate up to 3-fold increase in AAV yields, supporting greater efficiency and scalability across...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it...
New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation...
NEW BRUNSWICK, NEW JERSEY / ACCESS Newswire / November 6, 2025 / E&I Cooperative Services (E&I), the only member-owned, nonprofit...
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways:IAVI's Lassa vaccine candidate...
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways:IAVI's Lassa vaccine candidate...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)Narrows 2025 projected...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)Narrows 2025 projected...
LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with...
Business Activity Index at 54.3%; New Orders Index at 56.2%; Employment Index at 48.2%; Supplier Deliveries Index at 50.8% TEMPE,...
Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines". LOS ANGELES, Nov. 5, 2025...